25 of the Best Hematologist Oncologists Near Me in Gaithersburg, MD

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Thrombocytopenia, and Bone Marrow Transplant. Dr. Narang is board certified in American Board Of Internal Medicine. Dr. Narang is currently accepting new patients.

Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dezern is board certified in American Board Of Internal Medicine. Dr. Dezern is currently accepting new patients.

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine. Dr. Brodsky is currently accepting new patients.

Hibba Rehman is a Hematologist Oncology provider practicing medicine in Baltimore, Maryland. Dr. Rehman is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Melanoma, and Bone Marrow Aspiration. Dr. Rehman is board certified in American Board Of Internal Medicine - Medical Oncology, 2017 and American Board Of Internal Medicine - Hematology, 2017. Dr. Rehman is currently accepting new patients.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner-Johnston is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Wagner-Johnston is currently accepting new patients.

Dr. Shruti Chaturvedi is an Associate Professor of Medicine at Johns Hopkins. She received her medical degree from Maulana Azad Medical College, University of Delhi, India. She then completed a residency in Internal Medicine at the Cleveland Clinic, Cleveland, OH, and a fellowship in Hematology and Oncology at Vanderbilt University, Nashville, TN. She has additionally obtained a Master of Science in Clinical Investigation (MSCI) degree from Vanderbilt University. Dr. Chaturvedi specializes in the care of adults with non-malignant hematologic disorders including thrombocytopenic purpura, atypical hemolytic uremic syndrome, antiphospholpiid syndrome, immune thrombocytopenia, autoimmune hemolytic anemia, thrombotic, other bleeding and clotting disorders, and anemias. Her research is focused on improving the care of patients with thrombotic microangiopathies with a focus on long term sequelae, and the role of complement in thrombotic disorders such as the antiphospholipid syndrome. Dr. Chaturvedi is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Blood Clots, Splenectomy, and Bone Marrow Aspiration. Dr. Chaturvedi is currently accepting new patients.

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy. Dr. Jain is board certified in American Board Of Internal Medicine. Dr. Jain is currently accepting new patients.

Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program. She has served on the National Cancer Institute (NCI) Investigational Drug Steering Committee since 2014. Dr. Gojo received a Service Star Award from Johns Hopkins Medicine Service Excellence in 2018 for her exemplary care of leukemia patients. Dr. Gojo contributed to the clinical translational and drug development effort of multiple novel agents targeting pathogenic pathways in patients with acute leukemia. Her research efforts are now concentrated on the development and integration of novel immunotherapies into therapeutic armamentarium for patients with acute leukemia. She mentors basic and clinical research fellows and junior faculty on the development and design of novel clinical trials and mechanistic laboratory studies associated with these trials. She served as a leukemia team leader on the National Institute of Health (NIH)/NCI N01 grant (Phase II consortium) (2009-2011), and is co-principal investigator (PI) on the Experimental Therapeutics (ET)-Clinical Trial Network (CTN) UM1 grant supporting early clinical trials. Dr. Gojo has served on the National Comprehensive Cancer Network guideline panel for AML since 2019, Myeloid Growth Factor guideline panel since 2015 and previously served on the MPNs guideline panel (2016-2019). She has extensive experience in the regulatory aspects of drug development and served as the Chair (2015-2016) and Co-Chair (2014-2015) of the Cancer Research Review Committee at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, and serves as a member of the SKCCC Biostatistics Core Advisory Committee and SKCCC Clinical Research Office Coordinating Center Oversight Committee. Dr. Gojo is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Gojo is board certified in American Board Of Internal Medicine. Dr. Gojo is currently accepting new patients.

Dr. Ghiaur, a member of the Johns Hopkins Kimmel Cancer Center, is a physician-scientist whose primary interest is normal and malignant hematopoiesis, especially the role of the microenvironment in cell extrinsic drug resistance and persistence of minimal residual disease. He has distinguished himself as an outstanding laboratory-based investigator and a superior clinician. His research has translational potential in stem cell therapeutics, as well as acute leukemia and multiple myeloma. Dr. Ghiaur is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Ghiaur is board certified in American Board Of Internal Medicine. Dr. Ghiaur is currently accepting new patients.

Ravin Garg is a Hematologist Oncology specialist and an Oncologist practicing medicine in Easton, Maryland. Dr. Garg is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura. Dr. Garg is board certified in ABIM - Hematology - Hematology, 2010, ABIM - Medical Oncology - Medical Oncology, 2010, and American Board Of Internal Medicine. Dr. Garg is currently accepting new patients.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist practicing medicine in Lutherville, Maryland. She has been practicing medicine for over 17 years. Dr. Kalra is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Kalra is board certified in American Board Of Internal Medicine. Dr. Kalra is currently accepting new patients.

Edward Lee, M.D. was named one of Baltimore’s “Top Doc’s” by Baltimore Magazine in 2000 and 2002. After receiving additional training in Hematology and Medical Oncology at the University of Maryland in 1984, he remained on faculty until 1997. During his academic career, Dr. Lee was chairman of the training program for five years, started the Bone Marrow Transplant Program at the University of Maryland in 1993, and wrote 50 original articles on leukemia, lymphoma and related diseases. In 1997, Dr. Lee entered private practice as Chief of Hematology and Medical Oncology at Sinai Hospital. Practicing in Columbia since 2001, Dr. Lee treats patients with all forms of cancer, maintaining a particular interest in breast cancer, leukemia, and lymphomas. Learn more at marylandoncology.com. Dr. Lee is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Polycythemia Vera, and Paget Disease of the Breast. Dr. Lee is board certified in American Board Of Internal Medicine. Dr. Lee is currently accepting new patients.

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia. Dr. Mener is board certified in American Board Of Internal Medicine. Dr. Mener is currently accepting new patients.

"Shannon C. O'Connor, M.D., is a medical oncologist with Suburban Hospital. She practices out of Maryland Oncology Hematology. Dr. O'Connor has expertise in hematology and medical oncology with a special focus in women's health, including breast cancer and gynecologic cancers. Dr. O'Connor earned her Master's Degree in Physiology at Georgetown University, followed by her medical degree from St. George's University School of Medicine. She completed a residency at Washington Hospital Center, as well as a fellowship in hematology and oncology. Dr. O'Connor is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Montgomery County Medical Society and the American Medical Association. Selected Publications Catlett JP1, Williams SA, O'Connor SC, Krishnan J, Malkovska V. ""Primary lymphoma of bone: an institutional experience."" Leuk Lymphoma. 2008 Nov;49(11):2125-32. doi: 10.1080/10428190802404030.". Dr. O'connor is highly rated in 41 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, and Breast Cancer. Dr. O'connor is board certified in American Board Of Internal Medicine. Dr. O'connor is currently accepting new patients.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL), Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Swinnen is board certified in American Board Of Internal Medicine. Dr. Swinnen is currently accepting new patients.

Yudhishtra Markan is a Hematologist Oncology specialist and an Oncologist practicing medicine in Glen Burnie, Maryland. Dr. Markan is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Markan is board certified in American Board Of Internal Medicine and ABIM - Medical Oncology - Medical Oncology, 1995. Dr. Markan is currently accepting new patients.

Maria Baer is a Hematologist Oncology specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Baer is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Splenectomy. Dr. Baer is board certified in American Board Of Internal Medicine - Hematology, 1984 and American Board Of Internal Medicine - Internal Medicine, 1983. Dr. Baer is currently accepting new patients.

Mark Goldstein is a Hematologist Oncology provider practicing medicine in Bethesda, Maryland. Dr. Goldstein is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Childhood Iron Deficiency Anemia, Myelodysplastic Syndrome (MDS), Pleuropulmonary Blastoma, and Lung Cancer. Dr. Goldstein is board certified in American Board Of Internal Medicine. Dr. Goldstein is currently accepting new patients.

Gayatri Nimmagadda is a Hematologist Oncology specialist and an Oncologist practicing medicine in Glen Burnie, Maryland. Dr. Nimmagadda is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Pleuropulmonary Blastoma. Dr. Nimmagadda is board certified in American Board Of Internal Medicine, ABIM - Medical Oncology - Medical Oncology, 1995, and ABIM - Hematology - Hematology, 1994. Dr. Nimmagadda is currently accepting new patients.

Djordje Atanackovic is an Oncologist and a Hematologist Oncology provider practicing medicine in Baltimore, Maryland. Dr. Atanackovic is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Atanackovic is currently accepting new patients.

Mehmet Kocoglu is an Oncologist and a Hematologist Oncology provider practicing medicine in Baltimore, Maryland. Dr. Kocoglu is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kocoglu is board certified in American Board Of Internal Medicine - Hematology, 2014. Dr. Kocoglu is currently accepting new patients.

Arun Bhandari, M.D. is a native of Maryland and grew up in Silver Spring area. He earned his medical degree from Punjabi University and Government Medical College, Punjab, India and completed his internship and residency in Internal Medicine at New York University program in Queens, NY. He completed his Hematology and Oncology fellowship at University of Tennessee Health Science Center, Memphis, TN, Georgetown University and Washington Hospital Center, Washington, DC and NHLBI at National Institute of Health, Bethesda, MD. He served as a chief fellow at Georgetown University and Washington Hospital Center, Washington, D.C. After completing his fellowship in 2005, he joined as faculty at Allegheny General Hospital in Pittsburgh, PA, where he was actively involved in teaching fellows and residents. He joined COHA in 2007 at which time he opened a location in Annapolis and Kent Island. He has interest in head and neck cancer, brain cancer, breast cancer, lung cancer, gastrointestinal cancer(colon, pancreas, liver, gastric, esophageal etc.), genitourinary cancer (kidney, prostate, bladder etc.), gynecological cancer (ovarian, uterine, cervical, vaginal etc.), skin cancer, Lymphoma, Myeloma, Leukemia and various other blood disorders. He is a member of the American Society of Clinical Oncology and American Society of Hematology. He currently sees patients at Annapolis Cancer Center and Kent Island Center. He speaks English, Hindi, and Punjabi. Dr. Bhandari is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Multiple Myeloma, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia. Dr. Bhandari is board certified in ABIM - Medical Oncology - Medical Oncology, 2005, American Board Of Internal Medicine, and ABIM - Hematology - Hematology, 2006. Dr. Bhandari is currently accepting new patients.

Dr. Badros has extensive clinical experience in Bone Marrow Transplantation with special interest in multiple myeloma. He was involved in the initial trails of thalidomide and has conducted many clinical trials for treatment of relapsed and refractory multiple myeloma. Dr. Badros research has focused on evaluation of immunological approaches to eradicate residual myeloma cells in the high-risk setting following autologous stem cell transplantation using natural killer (NK) and interleukin -2 (IL-2) activated cells and non-myeloablative allogeneic donor grafts./p Dr. Badros is involved in the development of targeted novel therapeutics. He has completed a gene therapy trial using G-3039 Bcl-antisense. He evaluated the use of the proteosome inhibitor bortezomib in the newly diagnosed myeloma patients and evaluated the effects of bortezomib on stem cell. Currently, Dr. Badros is evaluating various combinations of novel therapies in multiple myeloma such as Lenalidomide and histone deacetylase inhibitors (SAHA) in relapsed myeloma patients alone and in combinations with dexamethasone and/or bortezomib./p. Dr. Badros is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Transplant. Dr. Badros is board certified in American Board Of Internal Medicine - Medical Oncology, 1995. Dr. Badros is currently accepting new patients.

Dr. Gloria F. Gerber is an Assistant Professor of Medicine at Johns Hopkins University in the Division of Hematology. She received her undergraduate degree in Biology with High. Dr. Gerber is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, and Hemolytic Anemia. Dr. Gerber is board certified in American Board Of Internal Medicine. Dr. Gerber is currently accepting new patients.

Dr. Alexander J. Ambinder is an instructor of medicine at the Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins. Dr. Ambinder has expertise in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and bone marrow transplantation. Dr. Ambinder received his B.A. from Washington University in St. Louis. He earned his M.D. from Emory University School of Medicine and his M.P.H. from Emory University Rollins School of Public Health. He completed the Osler Medical Residency Training Program in internal medicine at Johns Hopkins and subsequently served as an Assistant Chief of Service (Chief Resident). He completed his fellowships in Hematology and Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and also served as a Chief Fellow. Dr. Ambinder is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Ambinder’s principle research interest is in designing and conducting clinical trials inspired by laboratory insights to improve the management of acute myeloid leukemia and myelodysplastic syndrome. He also has an interest in building large databases that will yield insights that allow for more personalized approaches to the care and treatment of patients with blood cancers. Dr. Ambinder is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Childhood Acute Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Ambinder is board certified in American Board Of Internal Medicine. Dr. Ambinder is currently accepting new patients.